KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Cost of Revenue: 2018-2025

Historic Cost of Revenue for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to $18.7 million.

  • Castle Biosciences' Cost of Revenue rose 19.83% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.9 million, marking a year-over-year increase of 22.06%. This contributed to the annual value of $60.2 million for FY2024, which is 33.84% up from last year.
  • Latest data reveals that Castle Biosciences reported Cost of Revenue of $18.7 million as of Q3 2025, which was up 6.12% from $17.6 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Cost of Revenue peaked at $18.7 million during Q3 2025, and registered a low of $3.0 million during Q1 2021.
  • Its 3-year average for Cost of Revenue is $14.4 million, with a median of $14.5 million in 2024.
  • Data for Castle Biosciences' Cost of Revenue shows a peak YoY spiked of 107.90% (in 2022) over the last 5 years.
  • Castle Biosciences' Cost of Revenue (Quarterly) stood at $4.6 million in 2021, then spiked by 107.09% to $9.5 million in 2022, then surged by 30.49% to $12.4 million in 2023, then surged by 30.27% to $16.2 million in 2024, then climbed by 19.83% to $18.7 million in 2025.
  • Its last three reported values are $18.7 million in Q3 2025, $17.6 million for Q2 2025, and $16.4 million during Q1 2025.